Product image of Olmesartan Medoxomil/Amlodipine Accord (Olmesartan Medoxomil, Amlodipine) supplied by GNH India

Olmesartan Medoxomil/Amlodipine Accord

Active Ingredient:
Olmesartan Medoxomil, Amlodipine
Origin:
EU

Olmesartan Medoxomil/Amlodipine Accord (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Amlodipine Accord, is an angiotensin II receptor blocker presented as a fixed‑dose combination for oral use. It treats hypertension, often in adults who require more than one medication to reach blood‑pressure goals.

GNH India supplies Olmesartan Medoxomil/Amlodipine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan Medoxil/Amlodipine Accord is used in cardiovascular therapy, primarily targeting high blood pressure and related conditions.

  • Hypertension: Lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
  • Hypertensive heart disease: Improves cardiac workload by controlling blood pressure.
  • Chronic kidney disease with hypertension: Slows progression of renal impairment by maintaining target blood‑pressure levels.

How It Works

  • Olmesartan medoxil blocks the angiotensin II type‑1 (AT1) receptor, preventing vasoconstriction and aldosterone release, while amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combined effect produces additive blood‑pressure reduction through decreased peripheral resistance and lowered blood‑volume signaling.

Side Effects

Adverse reactions may occur with any antihypertensive combination and should be monitored.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Peripheral edema: swelling of ankles or feet.
  • Dizziness or light‑headedness: especially after standing.
  • Flushing: transient warmth sensation.
  • Fatigue: general tiredness.
  • Nausea: occasional upset stomach.

Serious or Rare Side Effects

  • Angio‑edema: rapid swelling of face, lips or throat.
  • Severe hypotension: symptomatic low blood pressure.
  • Hepatic dysfunction: elevated liver enzymes.
  • Acute kidney injury: sudden decline in renal function.
  • Myocardial infarction: rare but reported in vulnerable patients.
  • Hyperkalemia: elevated potassium levels.

Precautions & Warnings

When prescribing Olmesartan Medoxil/Amlodipine Accord, clinicians should consider several safety aspects.

  • Renal impairment: adjust monitoring and avoid in severe failure.
  • Hepatic disease: use with caution; monitor liver function.
  • Electrolyte imbalance: watch potassium levels, especially with diuretics.
  • Pregnancy: contraindicated in the second and third trimesters.
  • Elderly patients: start low and titrate slowly to reduce orthostatic effects.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Olmesartan Medoxil/Amlodipine Accord can interact with several medicines, requiring clinical awareness.

Major Interactions (Avoid)

  • Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of renal dysfunction and hyperkalaemia.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise amlodipine levels, risking hypotension.

Moderate Interactions (Monitor Closely)

  • Diuretics: additive blood‑pressure lowering effect; monitor volume status.
  • NSAIDs: may blunt antihypertensive response and affect renal function.
  • Lithium: possible increase in serum lithium concentrations.
  • Simvastatin: amlodipine can increase statin exposure, raising myopathy risk.
  • Alcohol: may enhance dizziness and hypotensive effects.

Frequently Asked Questions

Olmesartan Medoxomil/Amlodipine Accord is a fixed‑dose oral tablet that combines an angiotensin‑II receptor blocker with a calcium‑channel blocker. It is prescribed to lower high blood pressure in adults, especially when a single agent does not achieve target readings.

Olmesartan medoxil blocks the AT1 receptor for angiotensin II, preventing vasoconstriction and aldosterone‑driven fluid retention. Amlodipine relaxes vascular smooth muscle by inhibiting calcium entry, producing arterial dilation. Together they reduce peripheral resistance and lower blood‑pressure levels.

The specific dose of Olmesartan Medoxomil/Amlodipine Accord is determined by the prescribing clinician based on the patient’s blood‑pressure goals, renal function, age and concomitant therapies. Dosage adjustments are made individually and are not standardized across all patients.

Olmesartan medoxil is contraindicated in the second and third trimesters of pregnancy because of fetal toxicity risk, and it should be avoided unless clearly needed. Safety data for amlodipine during breastfeeding are limited; the combination should only be used if the potential benefit outweighs any possible risk to the infant.

To order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy, the Olmesartan‑amlodipine combo offers additive blood‑pressure reduction, often achieving target levels with a single tablet. It may be preferred over separate pills for adherence, and it provides a broader mechanism of action than either an ARB or a calcium‑channel blocker alone.

Store the tablets at ambient temperature, below 25 °C, in the original container. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf‑life.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the prescribing clinician’s instructions regarding timing and any dose adjustments.

Serious adverse events include angio‑edema, severe hypotension, acute kidney injury, hepatic dysfunction and hyper‑kalaemia. Patients should seek immediate medical attention if they experience rapid swelling of the face or throat, fainting, marked dizziness or sudden loss of kidney function.

The combination should be avoided in patients with known hypersensitivity to either component, in pregnant women beyond the first trimester, and in individuals with severe renal or hepatic impairment unless closely supervised by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT